Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.
作者信息
Wang Hongquan, Wu Shuang, Wang Yan, Tang Bo
机构信息
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
出版信息
Cancer Biol Med. 2022 Jul 21;19(7):945-7. doi: 10.20892/j.issn.2095-3941.2022.0299.
Abstract
摘要
Zotero 插件